SEC Form 3 · accession 0000899243-16-031911
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Oct 18, 2016
Accepted (ET)
Oct 18, 2016 · 7:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | holding | — | — | — | 5,105,330 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Bayer Global Investments B.V. ("Bayer BV") is the Direct Owner of 2,605,330 common shares of CRISPR Therapeutics AG ("CRISR"). Pursuant to a Subscription Agreement dated December 19, 2015, Bayer BV has agreed to purchase concurrently with the initial public offering of CRISPR in a private placement $35 million common shares at a price equal to the public offering price of $14.00, subject to the terms and conditions of the subscription agreement. This Form 3 is a joint filing of Bayer B.V. and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer Global Investments B.V. is the Direct Owner. The Subscription Agreement is incorporated by reference to Exhibit 4.1 of the Form S-1 Registration Statement of CRISPR Dated September 9, 2016.
Remarks
(2) Exhibit 24: Power of Attorney with respect to Bayer Global Investments B.V.